New drug combination for advanced lung cancer after prior treatments
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two newer drugs (sacituzumab tirumotecan and furmonertinib) together for patients with advanced non-squamous lung cancer whose tumors have specific genetic mutations and have stopped responding to earlier EGFR-targeted drugs and chemotherapy. The goal is to find out if this combination can help patients whose cancer has progressed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-squamous non-small cell lung cancer (NSCLC) that is advanced or cannot be surgically removed, with specific EGFR gene mutations (19del or L858R)
- Your cancer has stopped responding to at least one EGFR-targeted therapy (like erlotinib, gefitinib, or osimertinib) and to platinum-based chemotherapy
- You are between 18 and 75 years old and in good enough health to tolerate treatment (ECOG score 0 or 1)
- Your blood counts, liver, kidney, and heart function are within safe ranges for this study
- You can provide tumor tissue for testing or agree to a biopsy
- You are willing to use birth control during and for 6 months after the trial if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
This study tests a new combination of two targeted drugs—sacituzumab tirumotecan (an antibody-drug conjugate) and furmonertinib (an EGFR inhibitor)—for people with EGFR-mutant lung cancer that has worsened after first-line treatment with a third-generation EGFR pill. The goal is to see if this combo can help control the cancer better than current options.
This trial tests a combination of two newer drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
This study tests a new combination of two drugs (sacituzumab tirumotecan and another drug) for people with advanced esophageal cancer. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This study tests a new combination of drugs (sacituzumab tirumotecan plus a third-generation EGFR inhibitor) with or without radiation therapy for advanced lung cancer that has spread to the brain after prior EGFR inhibitor treatment. The goal is to see if this combination can better control the cancer and improve outcomes for patients with brain metastases.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.